

WHAT IS CLAIMED IS:

1. A compound of formula:



, or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

2. The compound according to claim 1, which is:



.

3. Use of a compound according to claim 1, or a pharmaceutically acceptable salt ~~or solvate~~ thereof, or claim 2, in the manufacture of a medicament.

4. Use of a compound according to claim 1, or a pharmaceutically acceptable salt ~~or solvate~~ thereof, or claim 2, in the manufacture of a medicament for reducing serum uric acid levels in a human.

5. Use of a compound according to claim 1, or a pharmaceutically acceptable salt ~~or solvate~~ thereof, or claim 2, in the manufacture of a medicament for treating hyperuricemia in a human.

6. Use of a compound according to claim 1, or a pharmaceutically acceptable salt ~~or solvate~~ thereof, or claim 2, in the manufacture of a medicament for treating hyperuricemia in a human with gout.

7. Use of a compound according to claim 1, or a pharmaceutically acceptable salt ~~or solvate~~ thereof, or claim 2, in the manufacture of a medicament for treating gout in a human.

8. Use of a compound according to claim 1, or a pharmaceutically acceptable salt ~~or solvate~~ thereof, or claim 2, in the manufacture of a medicament for treating or preventing a condition characterized by abnormal tissue or organ levels of uric acid in an individual.

9. The use according to claim 8, wherein the condition is gout, a recurrent gout attack, gouty arthritis, hyperuricaemia, hypertension, a cardiovascular disease, coronary heart disease, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, kidney stones, kidney failure, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis, sarcoidosis, hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency or a combination thereof.

10. The use according to any one of claims 3-9, in combination with a xanthine oxidase inhibitor.

11. The use according to claim 10, wherein the xanthine oxidase inhibitor is allopurinol.

12. The use according to claim 10, wherein the xanthine oxidase inhibitor is febuxostat.

13. A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt ~~or solvate~~ thereof, or claim 2, and a pharmaceutically acceptable carrier.

14. A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt ~~or solvate~~ thereof, or claim 2, together with a xanthine oxidase inhibitor and a pharmaceutically acceptable carrier.

15. The pharmaceutical composition according to claim 14, wherein the xanthine oxidase inhibitor is allopurinol.

16. The pharmaceutical composition according to claim 14, wherein the xanthine oxidase inhibitor is febuxostat.